Restructuring Charges	9 Months Ended
Sep. 30, 2022
Restructuring Charges [Abstract]
Restructuring Charges	13. Restructuring Charges On March 31, 2022, the Company initiated a plan to reduce its operating expenses, preserve financial resources, and focus its sales and marketing efforts on increasing utilization of CellFX Systems. The Company’s Board of Directors approved changes to the Company’s commercial leadership, restructuring of its commercial field organization and reductions in other personnel and expenses across the Company. The Company announced a reduction in force effective as of March 31, 2022. The affected employees were offered separation benefits, including severance payments along with temporary healthcare coverage assistance. The Company incurred a discrete restructuring related charge of $0.7 million which was fully recorded in March 2022 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the nine-month period ended September 30, 2022. This charge represents the total amount to be incurred in connection with the activity. During the three and nine-month periods ended September 30, 2022, the Company paid approximately $0.2 and $0.7 million of this balance, respectively. The remaining balance of $39.0 thousand is recorded in accrued expenses on the balance sheet at September 30, 2022. On September 20, 2022, the Company initiated an additional reduction in force to align its workforce with its shift in strategic direction to advance its core NPS technology outside of dermatology. The reduction primarily impacted dermatological sales, marketing and other related support personnel. The affected employees were offered separation benefits, including severance payments along with temporary healthcare coverage assistance. The Company incurred a discrete restructuring related charge of $0.2 million which was fully recorded in September 2022 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the three and nine-month periods ended September 30, 2022. During the three-month period ended September 30, 2022, the Company paid approximately $12.0 thousand of the balance and the remaining $0.2 million is recorded in accrued expenses on the balance sheet at September 30, 2022.

Restructuring Charges

9 Months Ended

Sep. 30, 2022

13. Restructuring Charges

On March 31, 2022, the Company initiated a plan to reduce its operating expenses, preserve financial resources, and focus its sales and marketing efforts on increasing utilization of CellFX Systems. The Company’s Board of Directors approved changes to the Company’s commercial leadership, restructuring of its commercial field organization and reductions in other personnel and expenses across the Company. The Company announced a reduction in force effective as of March 31, 2022. The affected employees were offered separation benefits, including severance payments along with temporary healthcare coverage assistance. The Company incurred a discrete restructuring related charge of $0.7 million which was fully recorded in March 2022 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the nine-month period ended September 30, 2022. This charge represents the total amount to be incurred in connection with the activity. During the three and nine-month periods ended September 30, 2022, the Company paid approximately $0.2 and $0.7 million of this balance, respectively. The remaining balance of $39.0 thousand is recorded in accrued expenses on the balance sheet at September 30, 2022.

On September 20, 2022, the Company initiated an additional reduction in force to align its workforce with its shift in strategic direction to advance its core NPS technology outside of dermatology. The reduction primarily impacted dermatological sales, marketing and other related support personnel. The affected employees were offered separation benefits, including severance payments along with temporary healthcare coverage assistance. The Company incurred a discrete restructuring related charge of $0.2 million which was fully recorded in September 2022 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the three and nine-month periods ended September 30, 2022. During the three-month period ended September 30, 2022, the Company paid approximately $12.0 thousand of the balance and the remaining $0.2 million is recorded in accrued expenses on the balance sheet at September 30, 2022.